Benefits of gemtuzumab ozogamicin outweigh risks, ODAC saysJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA grants priority review to sNDA for dasatinibJuly 12, 2017Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyCML
Common insurance plans exclude NCI, NCCN cancer centersJuly 9, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology Nursing
Mapping the genomic landscape of T-ALLJuly 6, 2017Leukemia, Myelodysplasia, TransplantationPediatricsALL
EC approves therapy for relapsed/refractory BCP-ALLJuly 4, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
FDA clears use of reagents to detect hematopoietic neoplasiaJuly 3, 2017CythemiasAnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAggressive Lymphomas
T-cell product improves outcomes of haplo-HSCTJune 29, 2017AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsTransplantation
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancerJune 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Company discontinues phase 3 trial of vadastuximab talirine in AMLJune 20, 2017Leukemia, Myelodysplasia, TransplantationAMLMyelodysplastic Syndrome
Neurotoxicity needs separate treatment from CRS in CAR T-cell therapyJune 18, 2017Leukemia, Myelodysplasia, TransplantationALL
CAR T cells plus ibrutinib induce CLL remissionsJune 17, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
‘Admirable’ overall survival attainable in AML with enasidenibJune 16, 2017Leukemia, Myelodysplasia, TransplantationAML
Deep molecular responses achievable in AML pts treated with gilteritinibJune 12, 2017Leukemia, Myelodysplasia, TransplantationAML
Majority of AML patients do not receive recommended molecular genetic testingJune 11, 2017Leukemia, Myelodysplasia, TransplantationAML
EU label for nilotinib now includes info on stopping therapyJune 9, 2017Leukemia, Myelodysplasia, TransplantationCML
